臨床試験サービス市場は、2025年の665億9000万ドルから2030年には1018億6000万ドルに成長し、予測期間中のCAGRは8.9%になると予想されます。臨床試験サービス市場の主要企業には、IQVIA Inc.(米国)、Thermo Fisher Scientific Inc.(米国)、Fortrea(米国)、ICON Plc(アイルランド)、Syneos Health(米国)、Laboratory Corporation of America Holdings(米国)、Medpace(米国)、Wuxi AppTec(中国)、Frontage Labs(米国)、Pharmaron(米国)、Tigermed(中国)、SGS Société Générale De Surveillance SA。(スイス)、Eurofins Scientific(ルクセンブルク)、リニカル(日本)、Parexel International Corporation(米国)、Worldwide Clinical Trials(米国)、Novotech(オーストラリア)、PSI(スイス)、Allucent(米国)、Premier Research(米国)、Clario(米国)、KCR S.A.(米国)、Rho, Inc.(米国)、Advanced Clinical(米国)などが含まれます。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 GLOBAL MARKET ESTIMATION
2.2.1 MARKET ESTIMATION METHODOLOGY
2.2.1.1 Insights from primary experts
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET
4.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY (2024)
4.3 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030)
4.4 CLINICAL TRIAL SERVICES MARKET, BY END USER (2024)
4.5 CLINICAL TRIAL SERVICES MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing focus on patient-centric trials (DCTs)
5.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing
5.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities
5.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid)
5.2.1.5 Technological integrations
5.2.2 OPPORTUNITIES
5.2.2.1 Increased focus on pediatric clinical trials
5.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials
5.2.2.3 Growing role of real-world evidence in drug approvals
5.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials
5.2.3 CHALLENGES
5.2.3.1 Cybersecurity or intellectual property concerns
5.2.3.2 Challenge of patient retention
5.2.3.3 Growing market competition
5.3 MARKET TRENDS
5.3.1 IN SILICO CLINICAL TRIALS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.5 PRICING ANALYSIS
5.5.1 PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE)
5.5.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2024
5.5.3 INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Clinical trial management system (CTMS)
5.9.1.2 Electronic data capture (EDC) systems
5.9.1.3 Randomization and trial supply management (RTSM)
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Telemedicine and wearable devices
5.9.2.2 AI and ML integration
5.10 KEY CONFERENCES AND EVENTS, 2025-2026
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY FRAMEWORK
5.11.1.1 North America
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.1.4 RoW
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER'S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET
5.14.1 INTRODUCTION
5.14.2 MARKET POTENTIAL FOR CLINICAL TRIALS
5.14.3 AI USE CASES
5.14.4 KEY COMPANIES IMPLEMENTING AI
5.14.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM
6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE
6.1 INTRODUCTION
6.2 CLINICAL TRIAL MANAGEMENT & MONITORING
6.2.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH
6.3 LABORATORY SERVICES
6.3.1 ANALYTICAL TESTING SERVICES
6.3.1.1 Increasing demand for analytical testing for drug development to drive market
6.3.2 BIOANALYTICAL TESTING SERVICES
6.3.2.1 Rising focus on biologics in advanced therapies to drive market
6.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES
6.4.1 BIOSTATISTICS
6.4.1.1 Integration of real-world data (RWD) into statistical analysis to support market growth
6.4.2 OTHER DATA MANAGEMENT SERVICES
6.5 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
6.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET
6.6 CONSULTING
6.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET
6.7 PATIENT RECRUITMENT & RETENTION
6.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH
6.8 MEDICAL WRITING
6.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET
6.9 SAFETY & PHARMACOVIGILANCE
6.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH
6.10 OTHER SERVICE TYPES
7 CLINICAL TRIAL SERVICES MARKET, BY PHASE
7.1 INTRODUCTION
7.2 PHASE III
7.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING
7.3 PHASE II
7.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS
7.4 PHASE I
7.4.1 DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH
7.5 PHASE IV
7.5.1 SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH
8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY
8.1 INTRODUCTION
8.2 SMALL MOLECULES
8.2.1 EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH
8.3 BIOLOGICS
8.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND
8.4 MEDICAL DEVICES & IVD
8.4.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND
9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET
9.3 NEUROLOGY
9.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET
9.4 RESPIRATORY DISORDERS
9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
9.5 METABOLIC DISORDERS/ENDOCRINOLOGY
9.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH
9.6 CARDIOVASCULAR SYSTEM DISORDERS
9.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET
9.7 DERMATOLOGY
9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH
9.8 GASTROINTESTINAL DISEASES
9.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET
9.9 IMMUNOLOGICAL DISORDERS
9.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH
9.10 INFECTIOUS DISEASES
9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET
9.11 PSYCHIATRY
9.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH
9.12 OPHTHALMOLOGY
9.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
9.13 HEMATOLOGY
9.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
9.14 GENITOURINARY & WOMEN'S HEALTH
9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
9.15 OTHER THERAPEUTIC AREAS
10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL
10.1 INTRODUCTION
10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
10.3.1 GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
10.4 HYBRID MODEL
10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH
11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN
11.1 INTRODUCTION
11.2 INTERVENTIONAL
11.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET
11.3 OBSERVATIONAL
11.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH
12 CLINICAL TRIAL SERVICES MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
12.2.1 INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
12.3 MEDICAL DEVICE COMPANIES
12.3.1 RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET
12.4 ACADEMIC INSTITUTES
12.4.1 RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA TO DRIVE MARKET
13 CLINICAL TRIAL SERVICES MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 Presence of well-established CROs to drive market
13.2.2 CANADA
13.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Growing R&D spending and favorable government policies to propel market
13.3.2 UK
13.3.2.1 Rising collaborations and improved policies to support market
13.3.3 FRANCE
13.3.3.1 Government-led support for effective drug research to drive market
13.3.4 ITALY
13.3.4.1 Government-led focus on improving clinical trial regulations to drive market
13.3.5 SPAIN
13.3.5.1 Rising R&D expenditure to boost market growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market
13.4.2 INDIA
13.4.2.1 Cost-efficient and innovation-driven approach to propel market
13.4.3 JAPAN
13.4.3.1 Decline in number of clinical trials to limit market
13.4.4 AUSTRALIA
13.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
13.4.5 SOUTH KOREA
13.4.5.1 Favorable government initiatives for drug development to drive market
13.4.6 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market
13.5.2 MEXICO
13.5.2.1 Increasing investments in pharma R&D to drive market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 GCC COUNTRIES
13.6.1.1 Saudi Arabia
13.6.1.1.1 Increase in collaborations to drive market
13.6.1.2 UAE
13.6.1.2.1 Growing clinical research activities to drive market
13.6.1.3 Rest of GCC countries
13.6.2 REST OF MIDDLE EAST
13.6.3 AFRICA
13.6.3.1 Expanding pharmaceutical industry to support market growth
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.3 REVENUE ANALYSIS
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Service type footprint
14.5.5.4 Phase footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of startups/SMEs
14.7 COMPANY VALUATION AND FINANCIAL METRICS
14.8 BRAND/SERVICE COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 SERVICE LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 IQVIA INC.
15.1.1.1 Business overview
15.1.1.2 Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Service launches
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 MnM view
15.1.1.4.1 Right to win
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 ICON PLC
15.1.2.1 Business overview
15.1.2.2 Services offered
15.1.2.3 Recent developments
15.1.2.3.1 Service launches
15.1.2.3.2 Deals
15.1.2.4 MnM view
15.1.2.4.1 Right to win
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses and competitive threats
15.1.3 THERMO FISHER SCIENTIFIC INC.
15.1.3.1 Business overview
15.1.3.2 Services offered
15.1.3.3 Recent developments
15.1.3.3.1 Service launches
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 MnM view
15.1.3.4.1 Right to win
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 FORTREA
15.1.4.1 Business overview
15.1.4.2 Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Service launches
15.1.4.3.2 Deals
15.1.4.3.3 Expansions
15.1.4.4 MnM view
15.1.4.4.1 Right to win
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 SYNEOS HEALTH
15.1.5.1 Business overview
15.1.5.2 Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Service launches
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Right to win
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.1.6.1 Business overview
15.1.6.2 Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Service launches
15.1.6.3.2 Deals
15.1.6.3.3 Expansions
15.1.6.4 MnM view
15.1.6.4.1 Right to win
15.1.6.4.2 Strategic choices
15.1.6.4.3 Weaknesses and competitive threats
15.1.7 MEDPACE
15.1.7.1 Business overview
15.1.7.2 Services offered
15.1.8 WUXI APPTEC
15.1.8.1 Business overview
15.1.8.2 Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 FRONTAGE LABS
15.1.9.1 Business overview
15.1.9.2 Services offered
15.1.9.3 Recent developments
15.1.9.3.1 Deals
15.1.9.3.2 Expansions
15.1.10 PHARMARON
15.1.10.1 Business overview
15.1.10.2 Services offered
15.1.11 TIGERMED
15.1.11.1 Business overview
15.1.11.2 Services offered
15.1.11.3 Recent developments
15.1.11.3.1 Service approvals
15.1.11.3.2 Deals
15.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA
15.1.12.1 Business overview
15.1.12.2 Services offered
15.1.13 EUROFINS SCIENTIFIC
15.1.13.1 Business overview
15.1.13.2 Services offered
15.1.14 LINICAL
15.1.14.1 Business overview
15.1.14.2 Services offered
15.1.14.3 Recent developments
15.1.14.3.1 Deals
15.1.14.3.2 Expansions
15.1.15 PAREXEL INTERNATIONAL CORPORATION
15.1.15.1 Business overview
15.1.15.2 Services offered
15.1.15.3 Recent developments
15.1.15.3.1 Service launches
15.1.15.3.2 Deals
15.1.15.3.3 Expansions
15.2 OTHER PLAYERS
15.2.1 WORLDWIDE CLINICAL TRIALS
15.2.2 PROPHARMA
15.2.3 NOVOTECH
15.2.4 PSI
15.2.5 ALLUCENT
15.2.6 PREMIER RESEARCH
15.2.7 CAIDYA
15.2.8 ERGOMED GROUP
15.2.9 CLARIO
15.2.10 PRECISION MEDICINE GROUP, LLC.
15.2.11 ADVANCED CLINICAL
15.2.12 EPS HOLDINGS, INC.
15.2.13 GUIRES INC. (PEPGRA)
15.2.14 KCR S.A.
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
